Brinavess Rejected By Advisory Cmte., Leaving US FDA To Mull Lifting Clinical Hold On Correvio's AFib Drug
Cardiovascular and Renal Drugs Advisory Committee voted 11-2 against approval for Correvio's atrial fibrillation drug Brinavess over cardiovascular safety concerns; the agency would have to lift the long-standing clinical hold on the drug before the company can do any further study in humans.
You may also be interested in...
Advanz Gets European Heft, Portfolio Assets In Correvio Buyout
Deal Snapshot: Building portfolio and commercial infrastructure in Europe, Advanz gets both at a modest price in acquiring Correvio.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Real-World Evidence Fails Another Test At US FDA
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.